Evidence map›Paper›PMID 34771587›Full record

ArticleCancers2021

Peanut-Shaped Gold Nanoparticles with Shells of Ceragenin CSA-131 Display the Ability to Inhibit Ovarian Cancer Growth In Vitro and in a Tumor Xenograft Model.

Ewelina Piktel, Ilona Oscilowska, Łukasz Suprewicz, Joanna Depciuch, Natalia Marcińczyk, Ewa Chabielska, Przemysław Wolak, Katarzyna Głuszek, Justyna Klimek, Piotr M Zieliński and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Green Synthesis of Gold Nanoflowers UsingAntibiotics (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Ewelina PiktelDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland.
Ilona OscilowskaDepartment of Analysis and Bioanalysis of Medicines, Medical University of Białystok, 15-089 Białystok, Poland.ORCID 0000-0002-7934-6973
Łukasz SuprewiczDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland.ORCID 0000-0001-6666-9688
Joanna DepciuchInstitute of Nuclear Physic, Polish Academy of Sciences, Radzikowskiego 152, 31-342 Krakow, Poland.ORCID 0000-0003-0168-1701
Natalia MarcińczykDepartment of Biopharmacy, Medical University of Białystok, 15-222 Białystok, Poland.ORCID 0000-0003-1454-647X
Ewa ChabielskaDepartment of Biopharmacy, Medical University of Białystok, 15-222 Białystok, Poland.
Przemysław WolakInstitute of Medical Science, Collegium Medicum, Jan Kochanowski University of Kielce, 25-001 Kielce, Poland.ORCID 0000-0003-4450-5011
Katarzyna GłuszekInstitute of Medical Science, Collegium Medicum, Jan Kochanowski University of Kielce, 25-001 Kielce, Poland.
Justyna KlimekDepartment of Human Anatomy, Medical University of Bialystok, 15-230 Białystok, Poland.
Piotr M ZielińskiInstitute of Nuclear Physic, Polish Academy of Sciences, Radzikowskiego 152, 31-342 Krakow, Poland.
Michał T MarzecLaboratory of Immuno-Endocrinology, Inflammation, Metabolism, and Oxidation Section, Department of Biomedical Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark.ORCID 0000-0001-9698-6019
Paul B SavageDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, UT 84604, USA.
Magdalena Parlińska-WojtanInstitute of Nuclear Physic, Polish Academy of Sciences, Radzikowskiego 152, 31-342 Krakow, Poland.ORCID 0000-0001-5901-400X
Robert BuckiDepartment of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, 15-222 Białystok, Poland.ORCID 0000-0001-7664-9226
Medical University of Białystok · PLInstitute of Nuclear Physics, Polish Academy of Sciences · PLJan Kochanowski University · PLBrigham Young University · USUniversity of Copenhagen · DK

Funding

Medical University of Bialystok SUB/1/DN/20/004/1122National Science Center UMO-2015/19/N/NZ6/01872
6 · The paper itself

Abstract

Gold nanoparticles-assisted delivery of antineoplastics into cancerous cells is presented as an effective approach for overcoming the limitations of systemic chemotherapy. Although ceragenins show great potential as anti-cancer agents, in some tumors, effective inhibition of cancer cells proliferation requires application of ceragenins at doses within their hemolytic range. For the purpose of toxicity/efficiency ratio control, peanut-shaped gold nanoparticles (AuP NPs) were functionalized with a shell of ceragenin CSA-131 and the cytotoxicity of AuP@CSA-131 against ovarian cancer SKOV-3 cells and were then analyzed. In vivo efficiency of intravenously and intratumorally administered CSA-131 and AuP@CSA-131 was examined using a xenograft ovarian cancer model. Serum parameters were estimated using ELISA methods. Comparative analysis revealed that AuP@CSA-131 exerted stronger anti-cancer effects than free ceragenin, which was determined by enhanced ability to induce caspase-dependent apoptosis and autophagy processes via reactive oxygen species (ROS)-mediated pathways. In an animal study, AuP@CSA-131 was characterized by delayed clearance and prolonged blood circulation when compared with free ceragenin, as well as enhanced anti-tumor efficiency, particularly when applied intratumorally. Administration of CSA-131 and AuP@CSA-131 prevented the inflammatory response associated with cancer development. These results present the possibility of employing non-spherical gold nanoparticles as an effective nanoplatform for the delivery of antineoplastics for the treatment of ovarian malignancy.

Indexed as

cerageninsdrug deliverygold nanopeanutsnanotechnologynon-spherical gold nanoparticlesovarian cancer

Identifiers

PMID34771587
PMCPMC8582422
OpenAlexW3211255817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.